The treatment of multiple myeloma has evolved significantly over the past 2 decades due to
the use of high-dose chemotherapy and autologous stem cell transplantation, and the …

Introduction: Treatment of multiple myeloma has undergone profound changes in the past
years thanks to the increased understanding of the biology of the disease and the new …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …

In spite of significant advances in the management of multiple myeloma (MM), the disease
remains incurable and nearly all patients ultimately relapse and require salvage …

Introduction: The introduction of autologous stem cell transplantation as well as novel agents
such as proteasome inhibitors (bortezomib) and immunomodulatory drugs (IMiDs; …

The development of bortezomib and immunomodulatory agents resulted in a revolution in
the treatment of multiple myeloma (MM). Moreover, second-generation proteasome …

Although multiple myeloma (MM) remains incurable, the introduction of novel agents has
improved clinical outcomes dramatically over the past 15 years. Response rates have risen …

At present, multiple classes of agents with distinct mechanisms of action are available for the
treatment of patients with multiple myeloma (MM), including alkylators, steroids …

In the past few years, multiple targeted therapies and immunotherapies including second
generation immunomodulatory drugs (pomalidomide) and proteasome inhibitors …

Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …